Teva Pharmaceutical Industries Ltd (TEVJF) Change in Accured Expenses (2025 - 2026)
Teva Pharmaceutical Industries' (TEVJF) quarterly Change in Accured Expenses came in at $82.0 million in Q2 2026, down 2.38% YoY from $84.0 million in Q2 2025, and up 156.94% on a QoQ basis from -$144.0 million in Q1 2026.
Teva Pharmaceutical Industries Ltd (TEVJF) Change in Accured Expenses (2025 - 2026) Analysis & Trends
Teva Pharmaceutical Industries (TEVJF) has 2 years of Change in Accured Expenses data on file, last reported at $82.0 million in Q2 2026.
- Quarterly Change in Accured Expenses fell 2.38% year-over-year to $82.0 million in Q2 2026, while the trailing twelve-month figure through Jun 2026 was -$19.0 million (changed N/A YoY) and the FY2025 annual result came in at -$15.0 million, down 105.81% from the prior year.
- Change in Accured Expenses rose to $82.0 million in Q2 2026, from -$144.0 million in the prior quarter.
- In the past five years, Change in Accured Expenses ranged from a high of $84.0 million in Q2 2025 to a low of -$144.0 million in Q1 2026.
Powered by 
Peer Comparison
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 82.00 Mn |
| Jun 30, 2026 | 82.00 Mn |
| Mar 31, 2026 | -144.00 Mn |
| Mar 31, 2026 | -144.00 Mn |
| Jun 30, 2025 | 84.00 Mn |
| Jun 30, 2025 | 84.00 Mn |
| Mar 31, 2025 | -41.00 Mn |
| Mar 31, 2025 | -41.00 Mn |